knowledge -WSS

knowledge

author：Wikipedia 2025-09-14 14:46:24 - browse：4

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Wikipedia

knowledge

WSS

EpiPen alternative approval delay highlights citizen petition issue

Why are Kaiser Permanente staff considering a strike?

EpiPen alternative approval delay highlights citizen petition issue

FDA panel endorses Alnylam’s heart drug — after picking it apart

A common UTI test for kids haunts adults as a traumatic 'nightmare'

What to make of Biden’s latest efforts on cancer research

focus

knowledge

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

What to make of Biden’s latest efforts on cancer research

United colonoscopy coverage change 'may cost lives,' doctors say

How AI helped researchers track recovery from depression

Alkermes shareholders re

WATCH: Why do bright lights make us see spots?

Drug repurposing or repositioning? The language matters

How to make the FDA’s new prescription one

In Memoriam: Notable people who died in 2023

FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

Microbiome research is starting to find links to chronic diseases

FDA panel to weigh approval of NurOwn, controversial ALS drug

STAT Virtual Event: Putting AI to the Test

Biotech lab space demand falls sharply

It's been 20 years since Dolly the sheep. Where's my clone?

White House touts steps to stem shortages of cancer treatments

Wikipedia

knowledge

focus

entertainment